1. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE). (September 2015) Authors: Middleton, M.; Dalle, S.; Corrie, P.; Loquai, C.; Terheyden, P.; Kähler, K.C.; Meiss, F.; Board, R.; Arance, A.M.; Gutzmer, R.; Tarhini, A.; Dummer, R.; Ernst, S.; Richtig, E.; Wolter, P.; Bulger, K.; Kotapati, S.; Le, T.K.; Brokaw, J.; Abernethy, A.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3353 Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse. (September 2015) Authors: Clark, L.; Hepburne-Scott, H.; Ottensmeier, C.; Middleton, M.; Myers, K.A.; Tarlton, A.; Petruckevitch, A.; Bassett, O.; Bonner, P.; Sharma, R.; Nathan, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Correlates of asthma morbidity in primary care. Issue 6823 (8th February 1992) Authors: Jones, K. P.; Bain, D. J.; Middleton, M.; Mullee, M. A. Journal: BMJ Issue: Volume 304:Issue 6823(1992) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. Issue 1 (January 2020) Authors: Peach, H.; Board, R.; Cook, M.; Corrie, P.; Ellis, S.; Geh, J.; King, P.; Laitung, G.; Larkin, J.; Marsden, J.; Middleton, M.; Moncrieff, M.; Nathan, P.; Powell, B.; Pritchard-Jones, R.; Rodwell, S.; Steven, N.; Lorigan, P. Journal: Journal of plastic, reconstructive & aesthetic surgery Issue: Volume 73:Issue 1(2020) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies. (December 2016) Authors: Postel-Vinay, S.; Herbschleb, K.; Massard, C.; Woodcock, V.; Ocker, M.; Wilkinson, G.; Walter, A.; Ewerton, F.; Poelman, M.; Middleton, M.; Soria, J.C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Imputation of values above an upper detection limit in compositional data. (March 2020) Authors: Mikšová, D.; Filzmoser, P.; Middleton, M. Journal: Computers & geosciences Issue: Volume 136(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Magnetic field strength of a neutron-star-powered ultraluminous X-ray source. (April 2018) Authors: Brightman, M.; Harrison, F.; Fürst, F.; Middleton, M.; Walton, D.; Stern, D.; Fabian, A.; Heida, M.; Barret, D.; Bachetti, M. Journal: Nature astronomy Issue: Volume 2:Number 4(2018) Page Start: 312 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. O6.4VX-970, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein. (17th March 2015) Authors: Asmal, M.; Dean, E.; Evans, J.; Middleton, M.; Plummer, R. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 2 Page Start: ii8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Operational application of numerical modelling for evaluation of hearth condition over a blast furnace campaign: Whyalla No. 2 Blast Furnace 4th campaign. (21st October 2022) Authors: Dong, X.F.; Zulli, P.; Tsalapatis, J.; Middleton, M. Journal: Ironmaking & steelmaking Issue: Volume 49:Number 9(2022) Page Start: 860 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PHARMACOKINETIC ANALYSIS AND CLINICAL RESULTS OF THE PHASE 1 DOSE ESCALATION AND EXPANSION CXD101 TRIAL IN RELAPSED, REFRACTORY LYMPHOMA. (June 2017) Authors: Eyre, T.A.; Folkes, L.; Collins, G.; Hildyard, C.; Stratford, M.; Myers, K.; La Thangue, N.; Kerr, D.; Middleton, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗